Answers are grounded in this paper and cite their sources.
Randomized trial evaluates a novel [18F]FDG-PET/CT endpoint in pulmonary sarcoidosis, suggesting improved measurement of treatment effects.
Rationale Traditional endpoints in sarcoidosis studies lack sensitivity to detect early anti-granulomatous effects. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) correlates with granulomatous activity and has demonstrated promise in small academic studies. The KITE study (NCT06205121, evaluating OATD-01 versus placebo, under double blind) implements a novel primary endpoint adapted from European Organization for Research and Treatment of Cancer (EORTC) oncology response criteria, representing a methodological innovation for proof-of-concept trials in pulmonary sarcoidosis. Methods The endpoint methodology integrates: 1) EORTC’s validated categorical response framework with sarcoidosis-specific 25% standardized uptake value maximum (SUVmax) thresholds based on prior studies showing reductions with effective treatments; and 2) Semi-quantitative assessment of up to 5 target lesions per anatomical region (pulmonary parenchyma, mediastinal/hilar nodes, extrathoracic sites). Lesions are delineated using a 41% SUVmax threshold with automated calculation of SUVmax, SUVmean, and SUVpeak. Central reading infrastructure employs blinded independent central review through validated web-based platforms using a single-read design. Quality control encompasses site qualification via Society of Nuclear Medicine and Molecular Imaging/Clinical Trials Network phantom validation, image de-identification, and technical review. Reader training includes consensus meetings establishing interpretation criteria, with performance monitored through independent quality monitoring. Sequential locked timepoint assessment minimizes inter-reader variability. Results The novel scoring system classifies patients by response category: complete, partial, stable disease, progression, or indeterminate, assessing target lesions, other pulmonary involvement and extrapulmonary disease, with the complete response defined as no pulmonary uptake above background without new lesions or > 25% SUVmax increase elsewhere (Table). The methodology quantifies both anti-granulomatous activity through SUV changes and disease extent through lesion volume/distribution. Feasibility assessments will help confirm the endpoint’s applicability in specialized centers with established sarcoidosis imaging protocols. Conclusions The KITE study establishes a reproducible, objective framework for assessing early therapeutic response in pulmonary sarcoidosis. This EORTC-adapted methodology provides standardized criteria suitable for multicenter implementation, potentially accelerating proof-of-concept evaluation of novel therapeutics. The KITE study with OATD-01 may be the first to confirm the utility of [18F]FDG-PET/CT as a biomarker-based endpoint for future sarcoidosis trials, addressing the critical need for sensitive, standardized outcome measures in this field.
No takes yet. Share an insight, caveat, or question.
Culver et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: